Akari Therapeutics Stock (NASDAQ:AKTX)
Previous Close
$1.08
52W Range
$0.85 - $4.40
50D Avg
$1.12
200D Avg
$2.29
Market Cap
$6.38K
Avg Vol (3M)
$40.67K
Beta
0.90
Div Yield
-
AKTX Company Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.